Working to change the lives of cancer patients: A video with CEO Jan van de Winkel
Genmab's CEO shares his perspective on how the company's work to develop innovative antibody therapeutics could change the lives of cancer patients in the future.
Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999 and is publicly traded on Nasdaq Copenhagen and under an ADR in the US. Genmab employs approximately 200 people with its headquarters and clinical development team in Denmark, research and development laboratories in The Netherlands and administrative functions in the United States.
The company’s first marketed antibody, ofatumumab (Arzerra®), is approved approved to treat chronic lymphocytic leukemia (CLL) patients who are refractory to fludarabine and alemtuzumab in all major markets. In the United States ofatumumab is also approved in the following indications:
- in combination with chlorambucil to treat previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate;
- for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL; and
- in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with relapsed CLL.
Ofatumumab is also approved in Europe in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. A subcutaneous formulation of ofatumumab is in clinical development for relapsing multiple sclerosis. Ofatumumab is marketed under an agreement with Novartis.
Genmab’s second product, daratumumab (DARZALEX®) is approved in the United States in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent. DARZALEX is also approved in Europe as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. Daratumumab is a CD38 monoclonal antibody being developed under a collaboration with Janssen Biotech, Inc. Daratumumab is also in clinical development as a single agent and in combination with other treatments for multiple myeloma, non-Hodgkin’s lymphoma (NHL), NKT-cell lymphoma, amyloidosis and solid tumors. Daratumumab was granted Breakthrough Therapy Designation by the U.S. FDA in May 2013 for patients with multiple myeloma who have received at least three different lines of therapy including both a PI and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent. In July 2016, daratumumab was granted a second Breakthrough Therapy Designation in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
In addition to daratumumab and ofatumumab, Genmab is building a deep pipeline of clinical and pre-clinical antibody products to treat cancer and for other diseases where there is an unmet medical need. Please see our Products in Development for more information on our pipeline.
Genmab uses both validated and next generation proprietary antibody technologies to provide the company with a steady stream of fully human antibody product candidates. These innovative product candidates, as well as the technologies themselves, are a key focus of Genmab’s strategy and interest in them has enabled the company to form alliances with top tier pharmaceutical and biotechnology companies.